Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.57 |
| ▸ | FLT4 | P35916 | 2/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | KIF5B | P33176 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050319 | 1.00 | KDR (0.61) | KDRPDGFRALCKBRAFRAF1 | |
| SCHEMBL2748037 | 0.82 | KDR (0.62) | KDRPDGFRABRAFRAF1PDGFRB | |
| SCHEMBL30702346 | 0.80 | KDR (0.64) | KDRPDGFRABRAFRAF1PDGFRB | |
| SCHEMBL29317879 | 0.79 | SMN1; SMN2 (0.44) | KDRPDGFRABRAFRAF1PDGFRB | |
| SCHEMBL29317895 | 0.79 | RAB9A (0.63) | KDRPDGFRBFLT4 | |
| SCHEMBL14967551 | 0.77 | KDR (0.67) | KDRPDGFRALCKRAF1PDGFRB | |
| SCHEMBL7480612 | 0.76 | KDR (1.00) | KDRPDGFRABRAFRAF1PDGFRB | |
| SCHEMBL29318810 | 0.76 | KDR (0.41) | KDRPDGFRABRAFRAF1PDGFRB | |
| SCHEMBL30051499 | 0.76 | KDR (0.41) | KDRPDGFRABRAFRAF1PDGFRB | |
| SCHEMBL6179904 | 0.76 | LCK (1.00) | KDRPDGFRALCKBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | KDR 4885/4885PDGFRA 4710/4885LCK 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.